The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Non‐alcoholic fatty liver disease
Abstract
Non‐alcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects a high proportion of the world’s population. Insulin resistance and oxidative stress play a critical role in the pathogenesis of NAFLD. Clinical, biochemical and imaging studies are of value in the diagnostic evaluation of patients with NAFLD, but liver biopsy remains the most sensitive and specific means of providing important diagnostic and prognostic information. Simple steatosis has the best prognosis within the spectrum of NAFLD, but NAFLD has the potential to progress to steatohepatitis, fibrosis and even cirrhosis. No effective medical therapy is currently available for all patients with NAFLD. In patients with diabetes mellitus and hyperlipidemia, appropriate metabolic control is always recommended, but rarely effective in resolving the liver disease. Weight reduction, when achieved and sustained, may improve the liver disease, although the results with weight loss have been inconsistent. Pharmacological therapy aimed at the underlying liver disease holds promise. Several medications with different mechanisms of action and potential benefit are currently being evaluated in clinical trials. Liver transplantation is a life‐extending therapeutic alternative for patients with end‐stage NAFLD, but NAFLD may recur after liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Fatty liver hepatitis and cirrhosis in obese patients
Adler, M., & Schaffner, F. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90740-x · Cited by 399
Non‐alcoholic steatohepatitis: another disease of affluence
James, *., & Day, C. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00163-4 · Cited by 271
Cited by
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Epidemiology of Non-Alcoholic Fatty Liver Disease
Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010) · Digestive Diseases · doi:10.1159/000282080 · Cited by 1,026
Bruce, K. D., Cagampang, F. R., Argenton, M., Zhang, J., Ethirajan, P. L., Burdge, G. C., Bateman, A. C., Clough, G. F., Poston, L., Hanson, M. A., et al. (2009) · Hepatology · doi:10.1002/hep.23205 · Cited by 449
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.023 · Cited by 420
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
Kakisaka, K., Cazanave, S. C., Fingas, C. D., Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., Mott, J. L., & Gores, G. J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00301.2011 · Cited by 222
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3977-1 · Cited by 218
Bruno, S., Maisonneuve, P., Castellana, P., Rotmensz, N., Rossi, S., Maggioni, M., Persico, M., Colombo, A., Monasterolo, F., Casadei-Giunchi, D., et al. (2005) · BMJ · doi:10.1136/bmj.38391.663287.e0 · Cited by 201
Non‐alcoholic steatohepatitis (NASH): where are we now and where are we going?
Day, C. P. (2002) · Gut · doi:10.1136/gut.50.5.585 · Cited by 181
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors
Dongiovanni, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12945 · Cited by 145
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Cimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101
Mottin, C. C., Moretto, M., Padoin, A. V., Kupski, C., Swarowsky, A. M., Glock, L., Duval, V., & da Silva, J. B. (2005) · Obesity Surgery · doi:10.1381/0960892054222830 · Cited by 97
Pizarro, M., Balasubramaniyan, N., Solís, N., Solar, A., Duarte, I., Miquel, J. F., Suchy, F. J., Trauner, M., Accatino, L., Ananthanarayanan, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037689 · Cited by 87
Sex Hormone-Binding Globulin Gene Expression and Insulin Resistance
Winters, S. J., Gogineni, J., Karegar, M., Scoggins, C., Wunderlich, C. A., Baumgartner, R., & Ghooray, D. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2640 · Cited by 79
Leptin in hepatocellular carcinoma
Wang, S.-N. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i46.5801 · Cited by 59
Xiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.006 · Cited by 56
Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?
Esquivel, C. M., Garcia, M., Armando, L., Ortiz, G., Lascano, F. M., & Foscarini, J. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3466-7 · Cited by 51
The effects of bariatric surgeries on nonalcoholic fatty liver disease
Aldoheyan, T., Hassanain, M., Al-Mulhim, A., Al-Sabhan, A., Al-Amro, S., Bamehriz, F., & Al-Khalidi, H. (2017) · Surgical Endoscopy · doi:10.1007/s00464-016-5082-8 · Cited by 47
Non-alcoholic fatty liver disease resolution following sleeve gastrectomy
Algooneh, A., Almazeedi, S., Al-Sabah, S., Ahmed, M., & Othman, F. (2016) · Surgical Endoscopy · doi:10.1007/s00464-015-4426-0 · Cited by 36
Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30
Effect on Liver Enzymes of Biliopancreatic Diversion: 4 Years of Follow-Up
Aller, R., Pacheco, D., Izaola, O., Primo, D., & de Luis, D. A. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000375506 · Cited by 10
Abdalgwad, R., Rafey, M. F., Murphy, C., Ioana, I., O’Shea, P. M., Slattery, E., Davenport, C., O’Keeffe, D. T., & Finucane, F. M. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00512-5 · Cited by 6
Metadata
- Authors
- ANGULO, P., & LINDOR, K. D.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 17
- Issue
- s1
- Pages
- S186-90
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1984180526
- Cited by
- 835
- References
- 4
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
